Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Laurus Labs share price today

LAURUSLABSAPI and CDMO pharmaConsolidatedPrices to 12 Nov 2026Results to Sep 2026

Price, 200-day average and NIFTY 500

The price is 50.8% above its 200-day average and 378 points ahead of the NIFTY 500 over 5 years

12 Nov 2026₹2,400.00Over 5 years: Laurus Labs +430.4%, NIFTY 500 +52.6%
₹500₹2,000Nov 22Nov 24Nov 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+140.2%3Y+86.3%/yr5Y+39.6%/yr10YToo short

EPS and P/E

EPS ₹24.82, up 96% in a year; P/E 96.7

12 Nov 2026₹24.82 EPS
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹30

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+95.7%3Y+53.7%/yr5YToo short10YToo short

Revenue and margins

Revenue up on a year for 8 quarters in a row; operating margin 34.0%, the highest on this chart

Sep 2026 quarter₹2,206 crore+33.5% on ₹1,653 crore a year earlier · NPM 19.8%
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹2,500

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+23.0%3Y+13.6%/yr5Y+7.2%/yr to Mar10Y+14.4%/yr to Mar
OPM average3Y24.1%5Y23.4% to Mar
NPM average3Y11.2%5Y10.7% to Mar

Return on capital

ROCE was 24.5% for the four quarters to Sep 2026, down from 25.8% in the year to Mar 2022

Four quarters to Sep 202624.5% ROCE
10%25%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y24.5%3Y11.2% to Mar5Y16.4% to Mar10Y17.4% to Mar

Profit and cash

Cash from operations was 158% of profit over five years, 182% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹1,624 crore operating cashProfit ₹890 crore · Free cash ₹554 crore
FY22
FY23
FY24
FY25
FY26
0₹1,750

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+95.3%3Y+53.0%/yr5Y−2.0%/yr to Mar10Y+20.8%/yr to Mar

Reinvestment

Capex was ₹1,070 crore in the year to Mar 2026, 2.2 times depreciation

FY26₹1,070 crore capexWork in progress ₹773 crore
FY22
FY23
FY24
FY25
FY26
0₹1,250

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+66.9% to Mar3Y+2.6%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Dec 2022Insufficient history, from Dec 2022

Debt ÷ equity 0.43 at 30 Sep 2026; profit covered interest 11.7x over the last four quarters

Sep 2026 balance sheet0.43 debt ÷ equityNet debt ₹2,596 crore
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
020x

Safety

Now3Y ago
Debt ÷ equity0.433Y ago0.53
Int. cover11.7x3Y ago3.9x

Operating health

Working capital rose from 43 to 58 days in 5 years

Year to Mar 202658 days working capital
100300Mar 22Mar 24Mar 26
Working cap.581Y+153Y−15Y+15
Debtor1151Y−173Y+195Y+16
Inventory3171Y+323Y+955Y+51

OwnershipInsufficient history, from Mar 2023Insufficient history, from Mar 2023

FIIs own 30.84%, up 4.67 points in a year. Promoters hold 27.47%

Share of the company held, %, by quarter end

Sep 2026 quarter30.84% FIIs
22%30%Sep 23Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y+4.673Y+6.81
Promoters1Y−0.133Y+0.27

Laurus Labs Ltd · LAURUSLABS · Pharma - API & CRAMS · price as of the 12 November 2026 close, updated every trading day · results updated weekly · research updated 29 October 2026

Laurus Labs share price today: ₹2,400.00 at the close on 12 November 2026, up 140.2% in a year. Laurus Labs (LAURUSLABS) is worth ₹1,29,675 crore, trades at a P/E of 96.7 and has closed between ₹930.20 and ₹2,405.50 over the past 52 weeks. Latest change: best operating margin in 16 quarters.

MixedBusiness trend from the last 12 quarters
₹2,400.00Price +140.2% in a year
96.7×P/E higher than 85% of the last 9.9 years
₹2,206 CrRevenue (Sep 2026) +33.5% on a year ago
₹436 CrProfit (Sep 2026) +124.7% on a year ago
34.0%Operating margin +9.6 points on a year ago
24.5%ROCE four quarters to Sep 2026
17.2%ROIC against a 12.0% cost of capital: +5.2 points

Laurus Labs Ltd's share price has risen faster than its earnings: +140.2% in a year, against +95.7% for earnings per share.

The main question: the share price moved +140.2% in a year while earnings per share (last four quarters) moved +95.7%. The difference came from the market paying a higher multiple.

The price has been rising for 149 weeks, and the P/E is higher than 85% of its own last 9.9 years. Over the last four quarters, results have been improving, with profit +124.7% on a year earlier, and 205% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.

What is the Laurus Labs share price today?

Laurus Labs Ltd's share price was ₹2,400.00 at the close on 12 November 2026. It has been rising for 149 weeks. That is 50.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹930 and ₹2,406, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Laurus Labs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 47 weeks in a row.

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 271 of 511 weeks

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
23 Dec 2016no NIFTY 500 reading
30 Dec 2016no NIFTY 500 reading
6 Jan 2017no NIFTY 500 reading
13 Jan 2017no NIFTY 500 reading
20 Jan 2017no NIFTY 500 reading
27 Jan 2017no NIFTY 500 reading
3 Feb 2017no NIFTY 500 reading
10 Feb 2017no NIFTY 500 reading
17 Feb 2017no NIFTY 500 reading
23 Feb 2017no NIFTY 500 reading
3 Mar 2017no NIFTY 500 reading
10 Mar 2017no NIFTY 500 reading
17 Mar 2017no NIFTY 500 reading
24 Mar 2017−8.8%
31 Mar 2017−7.8%
7 Apr 2017−4.0%
13 Apr 2017−8.1%
21 Apr 2017−2.5%
28 Apr 2017+0.3%
5 May 2017+1.8%
12 May 2017−7.5%
19 May 2017+4.7%
26 May 2017−1.0%
2 Jun 2017+9.2%
9 Jun 2017+15.0%
16 Jun 2017+6.2%
23 Jun 2017+15.1%
30 Jun 2017+14.8%
7 Jul 2017+15.1%
14 Jul 2017+12.5%
21 Jul 2017+8.8%
28 Jul 2017+7.1%
4 Aug 2017+0.8%
11 Aug 2017−5.4%
18 Aug 2017−8.5%
24 Aug 2017−10.0%
1 Sep 2017−13.7%
8 Sep 2017−18.0%
15 Sep 2017−15.3%
22 Sep 2017−14.1%
29 Sep 2017−20.6%
6 Oct 2017−15.1%
13 Oct 2017−14.6%
19 Oct 2017−12.4%
27 Oct 2017−14.5%
3 Nov 2017−14.0%
10 Nov 2017−6.4%
17 Nov 2017−8.2%
24 Nov 2017−3.6%
1 Dec 2017−5.5%
8 Dec 2017−10.3%
15 Dec 2017−9.2%
22 Dec 2017−8.7%
29 Dec 2017−1.4%
5 Jan 2018−7.7%
12 Jan 2018−7.3%
19 Jan 2018−8.9%
25 Jan 2018−3.4%
2 Feb 2018−5.6%
9 Feb 2018−6.8%
16 Feb 2018−0.4%
23 Feb 2018−4.3%
1 Mar 2018+1.7%
9 Mar 2018+2.6%
16 Mar 2018+3.9%
23 Mar 2018−1.5%
28 Mar 2018−2.5%
6 Apr 2018−3.9%
13 Apr 2018−4.4%
20 Apr 2018−1.3%
27 Apr 2018−4.9%
4 May 2018−3.1%
11 May 2018−5.3%
18 May 2018−11.5%
25 May 2018−10.2%
1 Jun 2018−16.7%
8 Jun 2018−9.5%
15 Jun 2018−7.9%
22 Jun 2018−9.3%
29 Jun 2018−10.6%
6 Jul 2018−7.1%
13 Jul 2018−6.1%
20 Jul 2018−13.4%
27 Jul 2018−12.5%
3 Aug 2018−10.6%
10 Aug 2018−14.4%
17 Aug 2018−12.2%
24 Aug 2018−12.4%
31 Aug 2018−10.5%
7 Sep 2018−13.9%
14 Sep 2018−14.1%
21 Sep 2018−11.8%
28 Sep 2018−4.8%
5 Oct 2018−7.8%
12 Oct 2018−6.7%
19 Oct 2018−4.5%
26 Oct 2018−15.3%
2 Nov 2018−13.6%
9 Nov 2018−7.7%
16 Nov 2018−0.7%
22 Nov 2018−2.1%
30 Nov 2018−4.9%
7 Dec 2018−5.3%
14 Dec 2018−11.1%
21 Dec 2018−6.9%
28 Dec 2018−12.1%
4 Jan 2019−11.4%
11 Jan 2019−13.4%
18 Jan 2019−8.2%
25 Jan 2019+7.1%
1 Feb 2019−5.8%
8 Feb 2019−5.5%
15 Feb 2019−16.9%
22 Feb 2019−13.0%
1 Mar 2019−13.2%
8 Mar 2019−12.4%
15 Mar 2019−1.6%
22 Mar 2019−6.0%
29 Mar 2019−1.6%
5 Apr 2019−2.9%
12 Apr 2019−0.2%
18 Apr 2019−1.1%
26 Apr 2019−4.0%
3 May 2019+10.5%
10 May 2019+8.4%
17 May 2019+5.4%
24 May 2019+2.2%
31 May 2019−1.5%
7 Jun 2019−2.4%
14 Jun 2019−12.1%
21 Jun 2019−15.7%
28 Jun 2019−16.8%
5 Jul 2019−9.6%
12 Jul 2019−7.9%
19 Jul 2019−6.0%
26 Jul 2019−6.3%
2 Aug 2019−10.4%
9 Aug 2019−9.4%
16 Aug 2019−1.8%
23 Aug 2019−3.3%
30 Aug 2019+1.7%
6 Sep 2019+4.2%
13 Sep 2019+7.5%
20 Sep 2019+7.7%
27 Sep 2019+14.1%
4 Oct 2019+5.6%
11 Oct 2019−6.1%
18 Oct 2019−13.3%
27 Oct 2019−3.6%
1 Nov 2019+2.5%
8 Nov 2019−0.4%
15 Nov 2019−8.7%
22 Nov 2019−8.3%
29 Nov 2019−4.2%
6 Dec 2019−7.1%
13 Dec 2019−11.3%
20 Dec 2019+4.7%
27 Dec 2019−9.3%
3 Jan 2020+0.3%
10 Jan 2020+12.7%
17 Jan 2020+23.2%
24 Jan 2020+14.1%
1 Feb 2020+10.4%
7 Feb 2020+15.7%
14 Feb 2020+25.5%
20 Feb 2020+33.4%
28 Feb 2020+23.4%
6 Mar 2020+33.7%
13 Mar 2020+38.6%
20 Mar 2020+27.1%
27 Mar 2020+22.9%
3 Apr 2020+16.9%
9 Apr 2020+31.1%
17 Apr 2020+23.9%
24 Apr 2020+42.2%
30 Apr 2020+44.0%
8 May 2020+24.0%
15 May 2020+25.6%
22 May 2020+25.0%
29 May 2020+24.7%
5 Jun 2020+16.2%
12 Jun 2020+15.8%
19 Jun 2020+20.9%
26 Jun 2020+39.3%
3 Jul 2020+32.2%
10 Jul 2020+26.9%
17 Jul 2020+38.6%
24 Jul 2020+30.7%
31 Jul 2020+62.1%
7 Aug 2020+110.9%
14 Aug 2020+104.0%
21 Aug 2020+123.4%
28 Aug 2020+132.3%
4 Sep 2020+139.0%
11 Sep 2020+137.0%
18 Sep 2020+171.2%
25 Sep 2020+136.0%
1 Oct 2020+154.6%
9 Oct 2020+160.7%
16 Oct 2020+146.3%
23 Oct 2020+124.2%
30 Oct 2020+63.7%
6 Nov 2020+23.8%
14 Nov 2020+30.9%
20 Nov 2020+13.4%
27 Nov 2020+22.1%
4 Dec 2020+19.9%
11 Dec 2020+13.2%
18 Dec 2020−3.7%
24 Dec 2020+7.9%
1 Jan 2021+4.5%
8 Jan 2021−15.0%
15 Jan 2021−10.3%
22 Jan 2021−9.4%
29 Jan 2021−16.6%
5 Feb 2021+3.2%
12 Feb 2021+10.7%
19 Feb 2021+11.4%
26 Feb 2021−7.0%
5 Mar 2021−7.7%
12 Mar 2021+1.6%
19 Mar 2021−6.9%
26 Mar 2021−4.9%
1 Apr 2021−3.0%
9 Apr 2021+18.0%
16 Apr 2021+20.8%
23 Apr 2021+16.6%
30 Apr 2021+29.1%
7 May 2021+41.9%
14 May 2021+22.9%
21 May 2021+29.2%
28 May 2021+45.0%
4 Jun 2021+50.2%
11 Jun 2021+58.7%
18 Jun 2021+54.8%
25 Jun 2021+73.7%
2 Jul 2021+76.3%
9 Jul 2021+49.3%
16 Jul 2021+37.8%
23 Jul 2021+31.3%
30 Jul 2021+29.2%
6 Aug 2021+28.8%
13 Aug 2021+41.1%
20 Aug 2021+30.9%
27 Aug 2021+16.6%
3 Sep 2021+8.8%
9 Sep 2021−3.9%
17 Sep 2021−2.0%
24 Sep 2021−18.2%
1 Oct 2021−19.7%
8 Oct 2021−19.0%
14 Oct 2021−18.0%
22 Oct 2021−31.2%
29 Oct 2021−29.0%
4 Nov 2021−38.5%
12 Nov 2021−45.7%
18 Nov 2021−35.9%
26 Nov 2021−22.2%
3 Dec 2021−23.4%
10 Dec 2021−19.3%
17 Dec 2021−21.2%
24 Dec 2021−16.3%
31 Dec 2021−14.7%
7 Jan 2022−19.2%
14 Jan 2022−19.4%
21 Jan 2022−6.0%
28 Jan 2022−3.2%
4 Feb 2022+9.4%
11 Feb 2022+25.9%
18 Feb 2022+18.1%
25 Feb 2022+5.4%
4 Mar 2022+12.2%
11 Mar 2022+12.9%
17 Mar 2022+16.4%
25 Mar 2022+17.3%
1 Apr 2022+11.2%
8 Apr 2022+18.5%
13 Apr 2022+19.8%
22 Apr 2022+26.7%
29 Apr 2022+22.6%
6 May 2022+15.0%
13 May 2022+3.8%
20 May 2022+10.4%
27 May 2022+7.3%
3 Jun 2022+3.9%
10 Jun 2022+2.2%
17 Jun 2022−8.2%
24 Jun 2022−11.0%
1 Jul 2022−11.0%
8 Jul 2022−10.2%
15 Jul 2022−8.7%
22 Jul 2022−12.9%
29 Jul 2022−13.8%
5 Aug 2022−12.3%
12 Aug 2022−5.3%
19 Aug 2022−10.1%
26 Aug 2022−8.5%
2 Sep 2022−7.6%
9 Sep 2022−15.2%
16 Sep 2022−7.4%
23 Sep 2022+0.4%
30 Sep 2022+0.5%
7 Oct 2022−0.5%
14 Oct 2022−7.6%
21 Oct 2022−10.8%
28 Oct 2022−19.1%
4 Nov 2022−18.6%
11 Nov 2022−21.4%
18 Nov 2022−25.3%
25 Nov 2022−23.8%
2 Dec 2022−29.1%
9 Dec 2022−27.8%
16 Dec 2022−25.9%
23 Dec 2022−30.3%
30 Dec 2022−29.7%
6 Jan 2023−31.8%
13 Jan 2023−33.4%
20 Jan 2023−28.7%
27 Jan 2023−18.9%
3 Feb 2023−25.3%
10 Feb 2023−21.3%
17 Feb 2023−21.5%
24 Feb 2023−22.3%
3 Mar 2023−20.4%
10 Mar 2023−14.9%
17 Mar 2023−15.1%
24 Mar 2023−15.0%
31 Mar 2023−17.5%
6 Apr 2023−16.2%
13 Apr 2023−8.2%
21 Apr 2023−11.5%
28 Apr 2023−12.9%
5 May 2023−7.7%
12 May 2023−11.2%
19 May 2023−10.6%
26 May 2023−1.8%
2 Jun 2023+3.7%
9 Jun 2023−2.1%
16 Jun 2023+9.1%
23 Jun 2023+3.7%
30 Jun 2023+12.3%
7 Jul 2023+8.5%
14 Jul 2023−2.1%
21 Jul 2023+1.9%
28 Jul 2023−0.5%
4 Aug 2023+14.4%
11 Aug 2023+15.7%
18 Aug 2023+12.8%
25 Aug 2023+8.1%
1 Sep 2023+6.6%
8 Sep 2023+11.5%
15 Sep 2023+1.5%
22 Sep 2023+3.7%
29 Sep 2023+4.7%
6 Oct 2023+4.6%
13 Oct 2023+12.6%
20 Oct 2023+16.2%
27 Oct 2023+6.4%
3 Nov 2023−8.6%
12 Nov 2023−9.0%
17 Nov 2023−7.0%
24 Nov 2023−9.3%
1 Dec 2023−12.5%
8 Dec 2023−13.5%
15 Dec 2023−11.4%
22 Dec 2023−4.0%
29 Dec 2023−4.3%
5 Jan 2024−4.9%
12 Jan 2024−9.4%
20 Jan 2024−15.8%
25 Jan 2024−12.2%
2 Feb 2024−8.7%
9 Feb 2024−7.3%
16 Feb 2024−6.1%
23 Feb 2024−4.9%
2 Mar 2024+2.8%
7 Mar 2024+5.2%
15 Mar 2024−0.6%
22 Mar 2024−8.1%
28 Mar 2024−15.2%
5 Apr 2024−4.4%
12 Apr 2024+1.4%
19 Apr 2024−0.4%
26 Apr 2024+9.3%
3 May 2024+11.0%
10 May 2024+7.4%
18 May 2024+5.7%
24 May 2024+3.9%
31 May 2024−4.7%
7 Jun 2024−8.0%
14 Jun 2024−4.7%
21 Jun 2024−3.6%
28 Jun 2024−2.7%
5 Jul 2024−1.2%
12 Jul 2024−8.8%
19 Jul 2024−7.3%
26 Jul 2024−9.3%
2 Aug 2024−10.4%
9 Aug 2024−11.9%
16 Aug 2024−13.4%
23 Aug 2024−9.4%
30 Aug 2024−0.6%
6 Sep 2024+2.8%
13 Sep 2024+8.7%
20 Sep 2024+0.1%
27 Sep 2024+3.2%
4 Oct 2024−9.4%
11 Oct 2024+0.3%
18 Oct 2024+8.2%
25 Oct 2024+7.0%
1 Nov 2024+11.0%
8 Nov 2024+20.5%
14 Nov 2024+19.0%
22 Nov 2024+18.8%
29 Nov 2024+23.4%
6 Dec 2024+23.3%
13 Dec 2024+17.5%
20 Dec 2024+27.7%
27 Dec 2024+34.1%
3 Jan 2025+43.2%
10 Jan 2025+32.1%
17 Jan 2025+25.8%
24 Jan 2025+36.0%
1 Feb 2025+24.6%
7 Feb 2025+33.0%
14 Feb 2025+18.2%
21 Feb 2025+11.7%
28 Feb 2025+5.3%
7 Mar 2025+10.0%
13 Mar 2025+9.1%
21 Mar 2025+14.3%
28 Mar 2025+9.5%
4 Apr 2025+2.3%
11 Apr 2025+4.5%
17 Apr 2025+6.7%
25 Apr 2025+0.1%
2 May 2025+2.9%
9 May 2025−15.8%
16 May 2025+0.8%
23 May 2025+2.2%
30 May 2025+3.0%
6 Jun 2025−2.7%
13 Jun 2025+6.2%
20 Jun 2025−3.0%
27 Jun 2025+3.7%
4 Jul 2025+19.4%
11 Jul 2025+20.8%
18 Jul 2025+26.3%
25 Jul 2025+29.3%
1 Aug 2025+34.2%
8 Aug 2025+38.7%
14 Aug 2025+40.7%
22 Aug 2025+48.2%
29 Aug 2025+40.3%
5 Sep 2025+38.3%
12 Sep 2025+32.2%
19 Sep 2025+43.7%
26 Sep 2025+21.2%
3 Oct 2025+13.3%
10 Oct 2025+11.4%
17 Oct 2025+7.4%
24 Oct 2025+6.6%
31 Oct 2025+7.8%
7 Nov 2025+14.5%
14 Nov 2025+12.9%
21 Nov 2025+6.1%
28 Nov 2025+16.6%
5 Dec 2025+15.1%
12 Dec 2025+12.8%
19 Dec 2025+9.2%
26 Dec 2025+26.2%
2 Jan 2026+24.1%
9 Jan 2026+23.1%
16 Jan 2026+23.5%
23 Jan 2026+13.4%
1 Feb 2026−1.4%
6 Feb 2026−3.0%
13 Feb 2026+2.3%
20 Feb 2026+6.5%
27 Feb 2026+9.8%
6 Mar 2026+4.0%
13 Mar 2026+5.8%
20 Mar 2026+4.4%
27 Mar 2026+5.3%
2 Apr 2026+2.1%
10 Apr 2026+5.2%
17 Apr 2026+4.8%
24 Apr 2026+10.5%
30 Apr 2026+19.6%
8 May 2026+34.5%
15 May 2026+35.7%
22 May 2026+35.1%
29 May 2026+25.5%
4 Jun 2026+39.1%
5 Jun 2026+41.7%
9 Jun 2026+39.1%
10 Jun 2026+29.4%
12 Jun 2026+31.6%
17 Jun 2026+22.3%
19 Jun 2026+23.7%
24 Jun 2026+29.5%
25 Jun 2026+31.8%
1 Jul 2026+18.2%
3 Jul 2026+13.1%
10 Jul 2026+11.4%
17 Jul 2026+9.3%
24 Jul 2026+10.2%
31 Jul 2026+21.1%
7 Aug 2026+24.6%
14 Aug 2026+24.6%
21 Aug 2026+25.1%
28 Aug 2026+39.9%
4 Sep 2026+29.8%
11 Sep 2026+36.5%
18 Sep 2026+35.9%
25 Sep 2026+37.4%
28 Sep 2026+36.4%
1 Oct 2026+35.4%
9 Oct 2026+39.4%
16 Oct 2026+31.5%
23 Oct 2026+17.1%
30 Oct 2026+38.1%
6 Nov 2026+31.5%
12 Nov 2026+33.5%
Each bar is one week, from 2016 to now (511 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 9.9 years the share price moved +2,423% while the NIFTY 500 moved +243%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Laurus Labs this quarter?

Three changes stood out: best operating margin in 16 quarters, revenue up on a year earlier for 8 quarters in a row and profit up on a year earlier for 8 quarters in a row.

  1. Best operating margin in 16 quarters

    Operating margin was 34% in the September 2026 quarter, against 24% a year earlier.

    Why: The share of sales left as operating profit rose because more of the sales came from higher-margin products and the company ran its operations more efficiently.

    Next results: check whether the company keeps its gross margin above 60% and its EBITDA margin, a measure of operating profit, above 30%.

    From the earnings call on 29 Oct 2026.

  2. Revenue up on a year earlier for 8 quarters in a row

    In the September 2026 quarter revenue was ₹2,206 crore, +33.5% on a year earlier.

    Why: Revenue rose because the company made much more medicine for other drug companies.

    Next results: check whether sales of medicine made for other drug companies hold up without customers running down their stock and the profit margin stays intact.

    From the earnings call on 29 Oct 2026.

  3. Profit up on a year earlier for 8 quarters in a row

    In the September 2026 quarter profit was ₹436 crore, +124.7% on a year earlier.

    Why: Profit rose much faster than sales because more of the sales came from higher-margin products and the company ran its operations more efficiently.

    Next results: check whether gross margin stays above 60% and EBITDA margin, a measure of operating profit, stays above 30%.

    From the earnings call on 29 Oct 2026.

What are Laurus Labs' latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Laurus Labs reported revenue of ₹2,206 crore, up 33.5% from ₹1,653 crore a year earlier, and a profit of ₹436 crore, up 124.7% from ₹194 crore.

Laurus Labs results: July to September 2026 against a year earlier

Laurus Labs results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹2,206 crore₹1,653 crore+33.5%
Profit₹436 crore₹194 crore+124.7%
Earnings per share₹8.17₹3.61+126.3%
Operating margin34.0%24.4%+9.6 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Laurus Labs' management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Laurus Labs share price history?

Laurus Labs closed at ₹2,400.00 on 12 November 2026, up 140.2% from ₹999.00 a year earlier (14 November 2025) and up 430.4% over five years. Its highest weekly close since December 2016 was ₹2,405.50 on 30 October 2026.

Laurus Labs share price: then and now

Laurus Labs share price: then and now
WhenCloseChange to 12 Nov 2026
1 week ago · 5 Nov 2026₹2,346.00+2.3%
1 month ago · 12 Oct 2026₹2,069.20+16.0%
6 months ago · 15 May 2026₹1,323.60+81.3%
1 year ago · 14 Nov 2025₹999.00+140.2%
3 years ago · 12 Nov 2023₹371.30+546.4%
5 years ago · 12 Nov 2021₹452.45+430.4%
10 years ago · 23 Dec 2016₹95.13+2,422.9%
Earliest weekly close in our records · 23 Dec 2016₹95.13+2,422.9%
Highest weekly close since December 2016, also the 52-week high · 30 Oct 2026₹2,405.50−0.2%
Lowest weekly close since December 2016 · 18 Oct 2019₹63.24+3,695.1%
52-week low (weekly close) · 1 Feb 2026₹930.20+158.0%

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 12 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

524 weekly closes from 23 December 2016 to 12 November 2026.

What is the latest news on Laurus Labs?

12 Nov 2026: Laurus Labs closed at ₹2,400.00, up 2.3% on the week and up 16.0% on the month. 6 Nov 2026: ex-date for an interim dividend of ₹1 a share.

Earlier

  • 29 Oct 2026: Laurus Labs held its results call for July to September 2026. Management guided: Gross margin above 60% and operating margin above 30% going forward.
  • Results for July to September 2026: Revenue up 33.5% and profit up 124.7% on a year earlier.
  • 8 May 2026: ex-date for an interim dividend of ₹1.20 a share.

What dividend does Laurus Labs pay?

Laurus Labs paid ₹2.20 a share in regular dividends in the 12 months to 12 November 2026 (2 payments), a yield of 0.09% at the ₹2,400.00 close on 12 November 2026. The last was an interim dividend of ₹1 a share, ex-date 6 November 2026.

Laurus Labs dividends since 1 April 2021

Laurus Labs dividends since 1 April 2021
Ex-dateDividend per shareTypeRecord date
6 Nov 2026Interim₹1Interimsame day
8 May 2026Interim₹1.20Interimsame day
31 Oct 2025Interim₹0.80Interimsame day
9 May 2025Interim₹0.80Interimsame day
6 Nov 2024Interim₹0.40Interimsame day
8 May 2024Interim₹0.40Interimsame day
2 Nov 2023Interim₹0.40Interimsame day
10 May 2023Interim₹1.20Interimsame day
3 Nov 2022Interim₹0.80Interim4 Nov 2022
10 May 2022Interim₹1.20Interim11 May 2022
17 Nov 2021Interim₹0.80Interim18 Nov 2021
11 May 2021Interim₹0.80Interim12 May 2021

Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.

5 of 5Of the last 5 financial years, years with an exchange dividend record

Yes. Laurus Labs Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years.

From the exchange corporate-actions record, read 12 November 2026.

What did Laurus Labs management say on the latest results call?

On the call for July to September 2026, held on 29 October 2026, Laurus Labs' management guided: Gross margin above 60% and operating margin above 30% going forward.

“Today, if any partner comes with a tech pack, we will not say no because we do not have the capabilities, except for monoclonal antibodies, cephalosporins, and penicillins. Those are the areas we do not have right now.”Dr Satyanarayana Chava, on the call for July to September 2026

What management guided

  • Peptide validation batches to begin in 12-18 months on commercial-scale block.
  • Peptide commercial revenues from current capacities around 2029 with high validation utilization.
  • LB-4 fermentation operational by end-2026 and KRKA JV Phase-1 blocks from mid-2027 with revenues in 2028-2029.
  • Capital spending ₹2,000 crore each in 2027 and 2028 then around ₹1,500 crore annually thereafter.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

What to watch in Laurus Labs' next results?

When Laurus Labs reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Peptide validation campaigns to commence on commercial block with high utilization - check start and scale per flagged window.

Laurus Labs: what to watch next quarter
What to check (from the call)
Peptide validation campaigns to commence on commercial block with high utilization - check start and scale per flagged window.
LB-4 facility to turn operational with trials and reserved volumes converting - check commissioning and uptake per flagged timeline.

Which stock lists is Laurus Labs on?

Laurus Labs is on 3 of our India lists: Momentum stocks, 52 week high & low and Pharma stocks.

Is Laurus Labs profitable?

Laurus Labs Ltd earned ₹436 Cr of net profit in the Sep 2026 quarter, +124.7% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹890 Cr. Over 10 years profit has grown 20.8% a year on average. The same quarter a year earlier earned ₹194 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The Sep 2026 quarter's profit is 19.8% of that quarter's revenue.

For the full year, FY26 profit was ₹890 Cr (+148.6% on the year before).

Why profit moved: revenue changed +33.5% on a year earlier and the margin moved +9.6 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +110.0% and revenue +23.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

How much revenue does Laurus Labs make, and is it growing?

Laurus Labs Ltd reported ₹2,206 Cr of revenue in the Sep 2026 quarter, +33.5% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 14.4% a year on average. The last full year, FY26, came in at ₹6,813 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹7,822 Cr.

FY26 revenue was ₹6,813 Cr, +22.7% on the year before.

Recent pace: the last four quarters grew +23.4% on average, against 14.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +23.0%, against +24.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +95.3%, against +218.9% a year (rolling over).

How much of every ₹100 of sales does Laurus Labs keep?

Laurus Labs Ltd's operating margin was 34.0% in the Sep 2026 quarter, 9.6 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.1% and 32.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +9.6 percentage points on the year while gross margin changed +3.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Is Laurus Labs' profit turning into cash?

Over the last 3 years, 205% of Laurus Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,624 Cr of operating cash against ₹890 Cr of profit. After ₹1,070 Cr of spending on assets, ₹554 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 205% of profit came in as cash: the cash cycle got 97 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 1.8× depreciation over three years. The next section checks what that spending is building.

Where does Laurus Labs' cash go?

Laurus Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 166 days in FY21. It spent ₹2,389 Cr on assets over the last 3 years. Customers take 115 days to pay, and stock sits for 317 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹6,813 Cr, each day of that cycle ties up about ₹18.7 Cr, so roughly ₹4,909 Cr is tied up in the business at any time.

FY26: customers took 115 days to pay and stock sat for 317 days, about 10.4 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 166.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 317 days. Customers pay about 115 days after that. Suppliers are paid at 170 days. Together that makes the 263-day cycle.

Spending on assets: ₹2,389 Cr over the last 3 years, against ₹1,295 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹773 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Laurus Labs' P/E ratio, and how does it compare with its own history?

Laurus Labs Ltd's P/E is 96.7×, near the high end of its own history: higher than 85% of past readings. Its usual P/E (the middle reading) is 35.7×, over 9.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

96.7×P/E · higher than 85% of its last 9.9 years
2.34PEG · today, derived from 3-year earnings growth

Why the multiple is where it is: over the past year earnings per share moved +95.7% while the price moved +140.2%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +86.3% a year; about +53.7% a year came from earnings growth and about +32.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Is the Laurus Labs business getting better or worse?

Laurus Labs Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +318.4% at its peak to +95.3%, but the business is still expanding, with ROCE rising at 24.5% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

FlatRevenue growth · latest (Sep 2026) +23.0%, range −18.1% to +27.4%
Turning downProfit growth · latest (Sep 2026) +95.3%, range −79.5% to +420.6%
Turning downEPS growth · latest (Sep 2026) +95.7%, range −79.7% to +421.4%
RisingROCE · latest (four quarters to Sep 2026) 24.5%, range 7.4% to 27.9%

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+22.7%+4.1%+7.2%+14.4%
Profit+148.6%+3.9%−2.0%+20.8%
EPS+147.9%+3.9%−2.1%+14.5%
Share price+140.2%+86.3%+39.6%—
+33.5%Revenue growth (Sep 2026) · latest quarter against a year ago
+124.7%Profit growth (Sep 2026) · latest quarter against a year ago
14.4%Revenue, 10 years · yearly growth over the long run

How much does Laurus Labs earn on its capital?

Laurus Labs Ltd earned a ROCE of 18% in FY26. That is up from a low of 7% in FY24. Its return on capital used (ROIC) is 5.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.1% net margin and 0.65× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 13.1% net margin × 0.65× asset turnover × 1.98× leverage (assets divided by equity) ≈ 16.9% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 17.2% − 12.0% = +5.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 17.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Does Laurus Labs have too much debt?

Laurus Labs Ltd has total debt of ₹2,625 Cr against shareholder equity of ₹6,061 Cr as of Sep 2026, so its debt is 0.43× its equity. Year by year, that ratio went from 0.53 in FY22 to 0.46 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

What is the Laurus Labs shareholding pattern?

Foreign institutions raised their stake in Laurus Labs Ltd by 4.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 30.8% of the company. Domestic institutions moved −1.2 points over the same period, to 11.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +4.8 points over 8 quarters, to 30.8%; Domestic institutions: −1.2 points over 8 quarters, to 11.9%; Promoters: +0.3 points over 8 quarters, to 27.5%.

Why the owners changed: foreign institutions drove it (+4.8 points), with the other side taken by domestic institutions (−1.2 points). They raised their stake step by step.

How far is Laurus Labs from balance-sheet trouble?

For Laurus Labs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Laurus Labs rank in its industry?

73.5 out of 100, rank 2 of 24 in Pharma - API & CRAMS, with 93% of the evidence available.

Laurus Labs Ltd scores 73.5 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 2. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.

The four parts add up to the total exactly: 32.2 + 17.4 + 6.8 + 17.1 = 73.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Laurus Labs compared with?

Laurus Labs ranks 2 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 73.5 out of 100.

  1. 1Acutaas Chemicals LtdMost evidence points up · 67% evidence79.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 40.2/43.75 · Revenue 41% · Profit 100% · Operating margin change 9 points · 95% evidenceCapital efficiency 26.4/31.25 · ROCE 31.6% (year to Mar 2026) · Operating margin 40.3% · 95% evidenceValuation 12.9/25 · P/E 74.5× · PEG — · 50% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 40.2 + 26.4 + 12.9 = 79.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  2. 2Laurus Labs Ltd this pageLAURUSLABS · leader · Most evidence points up · 93% evidence73.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 32.2/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidenceCapital efficiency 17.4/25 · ROCE 17.8% (year to Mar 2026) · Operating margin 34% · 100% evidenceValuation 6.8/20 · P/E 96.7× · PEG 2.34 · 65% evidenceRelative strength 17.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 39.1% · Strength vs NIFTY 500 (same reading) 62.9% · 1 year 140.2% · 100% evidence · 12 of 12 weeks aheadExact sum: 32.2 + 17.4 + 6.8 + 17.1 = 73.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  3. 3Gland Pharma LtdGLAND · leader · Most evidence points up · 100% evidence70.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.9/35 · Revenue 21.9% · Profit 56.3% · Operating margin change 5 points · 100% evidenceCapital efficiency 17.1/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 26.4% · 100% evidenceValuation 9.2/20 · P/E 44.1× · PEG 1.99 · 100% evidenceRelative strength 16.3/20 · Strength vs its industry (price vs its 52-week average, weekly) 19.3% · Strength vs NIFTY 500 (same reading) 41% · 1 year 80.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 27.9 + 17.1 + 9.2 + 16.3 = 70.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  4. 4Divis Laboratories LtdDIVISLAB · leader · Most evidence points up · 100% evidence65.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.6/35 · Revenue 21.6% · Profit 35.3% · Operating margin change 10 points · 100% evidenceCapital efficiency 19.5/25 · ROCE 22% (year to Mar 2026) · Operating margin 42.6% · 100% evidenceValuation 2.5/20 · P/E 90.7× · PEG 3.64 · 100% evidenceRelative strength 16.3/20 · Strength vs its industry (price vs its 52-week average, weekly) 17% · Strength vs NIFTY 500 (same reading) 39.6% · 1 year 76.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 27.6 + 19.5 + 2.5 + 16.3 = 65.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  5. 5Neuland Laboratories LtdNEULANDLAB · losing its lead · Most evidence points up · 100% evidence65.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.7/35 · Revenue 50.5% · Profit 88.4% · Operating margin change -8 points · 100% evidenceCapital efficiency 21.9/25 · ROCE 26.5% (year to Mar 2026) · Operating margin 21.8% · 100% evidenceValuation 10.3/20 · P/E 59.3× · PEG 1.87 · 100% evidenceRelative strength 6.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.8% · Strength vs NIFTY 500 (same reading) 12% · 1 year 19.8% · 100% evidence · 11 of 12 weeks aheadExact sum: 26.7 + 21.9 + 10.3 + 6.1 = 65 · What this means: Earnings are strong; relative strength in its sector is -5.8% and the one-year return is 19.8%.
  6. 6IOL Chemicals & Pharmaceuticals LtdIOLCP · leader · Evidence leans up · 90% evidence64.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 29.2/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidenceCapital efficiency 12.7/25 · ROCE 11.3% (year to Mar 2026) · Operating margin 13.7% · 100% evidenceValuation 9.2/20 · P/E 29.6× · PEG — · 50% evidenceRelative strength 13.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 26.2% · Strength vs NIFTY 500 (same reading) 45.9% · 1 year 114.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 29.2 + 12.7 + 9.2 + 13.2 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Shilpa Medicare LtdSHILPAMED · leader · Evidence leans up · 93% evidence63.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.6/35 · Revenue 37.4% · Profit 100% · Operating margin change -2 points · 100% evidenceCapital efficiency 12.2/25 · ROCE 10.9% (year to Mar 2026) · Operating margin 26.8% · 100% evidenceValuation 12.1/20 · P/E 58.2× · PEG 1.53 · 65% evidenceRelative strength 15.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 45.3% · Strength vs NIFTY 500 (same reading) 66.2% · 1 year 160.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.6 + 12.2 + 12.1 + 15 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Morepen Laboratories LtdMOREPENLAB · leader · Evidence leans up · 75% evidence62.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidenceCapital efficiency 9.3/25 · ROCE 8.1% (year to Mar 2026) · Operating margin 16.5% · 100% evidenceValuation 9.8/20 · P/E 27.6× · PEG — · 50% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 45.3% · 1 year 105.1% · 25% evidence · 12 of 12 weeks aheadExact sum: 31.8 + 9.3 + 9.8 + 11.9 = 62.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Sai Life Sciences LtdSAILIFE · leader · Evidence leans up · 93% evidence58.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.4/35 · Revenue 15.5% · Profit 31.1% · Operating margin change 1 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 28.2% · 100% evidenceValuation 3.8/20 · P/E 107.3× · PEG 4.33 · 65% evidenceRelative strength 18.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 27.1% · Strength vs NIFTY 500 (same reading) 50.5% · 1 year 118.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.4 + 15.8 + 3.8 + 18.5 = 58.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10Anthem Biosciences LtdANTHEM · leader · Evidence leans up · 93% evidence58.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.5/35 · Revenue -1.2% · Profit 19% · Operating margin change 6 points · 100% evidenceCapital efficiency 23.6/25 · ROCE 30.4% (year to Mar 2026) · Operating margin 45.6% · 100% evidenceValuation 5.0/20 · P/E 86× · PEG 4.28 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.9% · Strength vs NIFTY 500 (same reading) 19.1% · 1 year 38.2% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.5 + 23.6 + 5 + 11.9 = 58 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.
  11. 11SMS Pharmaceuticals LtdSMSPHARMA · breaking out · Evidence leans up · 90% evidence56.6out of 100GrowthCapitalValuationRelative
  12. 12Windlas Biotech LtdWINDLAS · leader · Evidence leans up · 75% evidence52.4out of 100GrowthCapitalValuationRelative
  13. 13Granules India LtdGRANULES · quiet · Evidence leans up · 100% evidence51.3out of 100GrowthCapitalValuationRelative
  14. 14Solara Active Pharma Sciences LtdSOLARA · breaking out · Evidence leans down · 74% evidence49.3out of 100GrowthCapitalValuationRelative
  15. 15Blue Jet Healthcare LtdBLUEJET · basing · Evidence leans down · 85% evidence47.4out of 100GrowthCapitalValuationRelative
  16. 16Concord Biotech LtdCONCORDBIO · quiet · Evidence leans down · 85% evidence45.8out of 100GrowthCapitalValuationRelative
  17. 17Piramal Pharma LtdPPLPHARMA · leader · Evidence leans down · 71% evidence43.7out of 100GrowthCapitalValuationRelative
  18. 18Supriya Lifescience LtdSUPRIYA · quiet · Evidence leans down · 90% evidence41.9out of 100GrowthCapitalValuationRelative
  19. 19Hikal LtdHIKAL · quiet · Evidence leans down · 78% evidence39.0out of 100GrowthCapitalValuationRelative
  20. 20Syngene International LtdMost evidence points down · 67% evidence33.6out of 100GrowthCapitalValuationRelative
  21. 21OneSource Specialty Pharma LtdONESOURCE · turning · Most evidence points down · 80% evidence31.3out of 100GrowthCapitalValuationRelative
  22. 22Jubilant Pharmova LtdJUBLPHARMA · turning · Most evidence points down · 86% evidence29.7out of 100GrowthCapitalValuationRelative
  23. 23Dishman Carbogen Amcis LtdDCAL · basing · Most evidence points down · 64% evidence26.3out of 100GrowthCapitalValuationRelative
  24. 24Cohance Lifesciences LtdCOHANCE · quiet · Most evidence points down · 82% evidence22.9out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API & CRAMS, all 24 compared on one page.

Which companies are close to Laurus Labs in size?

Laurus Labs is the 2nd largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (at the 12 November 2026 close). Just above it: Divis Laboratories. Just below it: Gland Pharma, Anthem Biosciences, Sai Life Sciences, Acutaas Chemicals and Piramal Pharma.

Pharma - API & CRAMS companies close in size

  1. Divis Laboratories Ltd ₹3,04,891 crore
  2. Laurus Labs Ltd ₹1,29,675 crore
  3. Gland Pharma Ltd ₹54,597 crore
  4. Anthem Biosciences Ltd ₹52,879 crore
  5. Sai Life Sciences Ltd ₹40,481 crore
  6. Acutaas Chemicals Ltd ₹32,716 crore
  7. Piramal Pharma Ltd ₹32,628 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

  1. Siemens Ltd ₹1,30,728 crore · Capital Goods - Electric General
  2. HDFC Life Insurance Company Ltd ₹1,29,877 crore · Finance - Insurance
  3. Laurus Labs Ltd ₹1,29,675 crore
  4. CG Power & Industrial Solutions Ltd ₹1,29,465 crore · Capital Goods - Transformers
  5. LTM Ltd ₹1,27,674 crore · IT - Software

What else do people ask about Laurus Labs?

What were Laurus Labs's latest quarterly results?

Laurus Labs Ltd reported revenue of ₹2,206 Cr and net profit of ₹436 Cr for the Sep 2026 quarter. Revenue rose 33.5% and profit rose 124.7% compared with a year earlier. Earnings per share were ₹8.17.

The operating margin was 34.0%, 9.6 percentage points higher than a year earlier (as of 12 November 2026).

What is Laurus Labs's market cap?

Laurus Labs Ltd's market capitalisation is ₹1,29,675 Cr at a share price of ₹2,400.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 12 November 2026).

How is Laurus Labs performing?

Laurus Labs Ltd's share price has been rising for 149 weeks. In its latest quarter, revenue rose 33.5% and profit rose 124.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 47 weeks running (as of 12 November 2026).

Will Laurus Labs's share price go up?

This page does not forecast Laurus Labs Ltd's share price. What it shows instead: the share price is ₹2,400.00, and it has been rising for 149 weeks. Its P/E of 96.7× is higher than 85% of its own last 10 years (as of 12 November 2026).

Who owns Laurus Labs?

Promoters own 27.5% of Laurus Labs Ltd, foreign institutions 30.8%, domestic institutions 11.9% and the public 29.9% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 4.8 percentage points over 8 quarters (as of 12 November 2026).

Where is Laurus Labs in its business cycle?

Laurus Labs Ltd's FY26 operating margin was 26.2%, against a 13-year range of 15.1% to 32.2%. The latest quarter was 34.0%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 12 November 2026).

What could break the Laurus Labs story?

The main question: the share price moved +140.2% in a year while earnings per share (last four quarters) moved +95.7%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 12 November 2026).

Is Laurus Labs a stock worth studying right now?

What the numbers show: Laurus Labs Ltd's share price has risen faster than its earnings: +140.2% in a year, against +95.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 12 November 2026).

Is there a Laurus Labs share price forecast for 2026?

What management itself guided: Gross margin above 60% and operating margin above 30% going forward.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 12 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.